Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 and PD-1 Monoclonal Antibody in HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06423885Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M07D1 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Biokin Pharmaceutical. Primary endpoints: Objective Response Rate at 24 months and Recommended Phase II Dose at 24 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
BL-M07D1
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06423885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423885.